Compare Novartis AG (NVS) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard High Dividend Yield ETF — how do they compare? Novartis AG trades at $137.51 (market cap $262.64B), while Vanguard High Dividend Yield ETF trades at $162.62. The key difference: Novartis AG pays a 3.44% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VYM | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | — |
52-Week High | $168.62 | $167.03 |
52-Week Low | $121.80 | $137.47 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% amid recent clinical trial setbacks, yet maintains strong fundamentals with a 24.67% net income margin and $13.98B net income for 2025. Technical indicators show a bullish trend with support at $158, while earnings have been mixed, beating in Q2 2026 but missing in Q1. The company's cash flow from operations remains robust at $19.14B, though pipeline challenges have sparked negative sentiment.
Outlook is cautious due to drug trial failures pressuring future growth, but solid profitability and a buy-heavy analyst consensus (24% buy rating) suggest long-term value. Key risks include pipeline volatility and competitive threats, yet institutional holdings and a low debt profile provide stability. Investors should weigh recent declines against fundamental strength.
VYM trades at $163.52, down 0.43% on the day, with a neutral technical signal overall. The ETF has demonstrated strong performance in 2026 with a 16% total return year-to-date, outperforming the broader market with lower volatility. Recent analysis highlights its attractive valuation with a forward P/E of 18.85x compared to SPY's 20-21x, providing a higher earnings yield. The fund maintains a diversified portfolio with significant financial sector exposure, benefiting from the current interest rate environment.
The outlook for VYM remains positive with compelling valuation metrics and technical strength. Investment opportunities include above-market dividend yield, sector diversification, and lower volatility compared to broad market ETFs. Key risks include interest rate sensitivity due to financial sector concentration and potential yield compression if dividend growth doesn't keep pace with rising stock prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
